celecoxib

AssetSmall moleculeAlso F14, YM177, DFN-15 Active, CELBESTA®

Selective cyclooxygenase-2 inhibitor reducing prostaglandin synthesis to relieve pain and inflammation

Stage: Approved
Modality: Small molecule
Target: Inflammation
Indications: 39
Trials: 379
Developers: 11

Indications

39

Acute pain
Approvedaccessdata.fda.gov7 Oct 2026
Adenomatous polyposis coli
Approvedema.europa.eu7 Oct 2026
Arthritis, Juvenile Rheumatoid
Approvedaccessdata.fda.gov7 Oct 2026

36 more

Targets and what it contains3
Owner and partners11
Trials379
Evidence for its targets3
Competitors12
Aging relevance2
Signals8

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026 · 54 sources